MoneyWorks4Me

USFDA completes cGMP inspection of Biocon’s Bangalore facility

24 Sep 2018 Evaluate

US Food and Drug Administration (USFDA) has conducted a periodic cGMP inspection of Biocon’s Drug Substance manufacturing site at Bangalore Campus from September 17 - 21, 2018. After the inspection there was no observations found. The successful audit of this site reflects the company’s strong commitment to cGMP compliance.

Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation-driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.

Peers
Company Name CMP
Sun Pharma. Inds. 1782.00
Dr. Reddys Labs. 1208.00
Cipla 1334.00
Lupin 2010.00
Zydus Lifesciences 1138.50
View more..